Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2009

PPD to Acquire AbCRO

  • PPD entered into an agreement to acquire AbC.R.O. (AbCRO),  a contract research organization operating in Central and Eastern Europe. As a result of the acquisition, PPD gains immediate entry into Romania, Bulgaria, Serbia, and Croatia with established infrastructure and expertise. PPD will also bolster its existing staff and operations in Poland, Russia, and Ukraine.

    Founded in 2000, AbCRO provides a range of Phase II–IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs. AbCRO employs more than 230 full-time professionals, many of whom have worked extensively with PPD over the past three years.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »